Omthera Pharmaceuticals

Omeicos Therapeutics

The company develops synthetic lipid mediators to treat patients with cardiovascular, ophthalmic and primary mitochondrial diseases.

Staten Biotechnology

This company develops monoclonal antibody therapies for patients with dyslipidaemia to reduce cardiovascular risk and lower triglyceride levels.

OxThera AB

This biopharmaceutical company develops bacteria-based therapies to treat patients with primary hyperoxaluria and other rare kidney diseases.

Shifa

This biopharmaceutical company develops oral small molecule drugs to treat cardiovascular disease and dyslipidemia for patients with high cholesterol.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.

Cerenis Therapeutics Holding SA

This biopharmaceutical company develops high-density lipoprotein therapies to treat patients with cardiovascular and metabolic diseases, as well as renal and oncology conditions.

NewAmsterdam Pharma

The company develops oral therapies to lower cholesterol in patients with cardiovascular disease whose symptoms are inadequately managed by standard statin treatments.

Corteria

This biopharmaceutical company develops therapeutic drugs for patients with obesity and heart failure subpopulations.